Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults. - Test2 - elhamkhani - TriplyDB

Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

http://www.wikidata.org/entity/Q41743964

about

The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and Control A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review Tropical and travel-associated norovirus: current concepts Norovirus Norovirus immunology: Of mice and mechanisms Identification of the novel Kawasaki 2014 GII.17 human norovirus strain in Italy, 2015.A Rapid Epidemiological Tool to Measure the Burden of Norovirus Infection and Disease in Resource-Limited Settings B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.Developments in understanding acquired immunity and innate susceptibility to norovirus and rotavirus gastroenteritis in children Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial Identification of a novel cellular target and a co-factor for norovirus infection - B cells & commensal bacteria.Llama nanoantibodies with therapeutic potential against human norovirus diarrhea.Virus Genotype Distribution and Virus Burden in Children and Adults Hospitalized for Norovirus Gastroenteritis, 2012-2014, Hong Kong.Serological Correlates of Protection against a GII.4 Norovirus.An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coli.Innate Resistance and Susceptibility to Norovirus Infection Vomiting as a Symptom and Transmission Risk in Norovirus Illness: Evidence from Human Challenge Studies.Norovirus Gastroenteritis in a Birth Cohort in Southern India Modelling Estimates of Norovirus Disease in Patients with Chronic Medical Conditions.Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.Norovirus vaccines and potential antinorovirus drugs: recent advances and future perspectives Burden of norovirus in healthcare facilities and strategies for outbreak control.Host Genetic Susceptibility to Enteric Viruses: A Systematic Review and Metaanalysis.Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation Immunization in Canada: Update for 2015.Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB.Current tools for norovirus drug discovery Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine.Norovirus vaccines: Correlates of protection, challenges and limitations Comparison of norovirus genogroup I, II and IV seroprevalence among children in the Netherlands, 1963, 1983 and 2006.Epidemiology of Norovirus Infection Among Immunocompromised Patients at a Tertiary Care Research Hospital, 2010-2013.Identification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses.Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations.Molecular epidemiology of norovirus in children and the elderly in Atlanta, Georgia, United States.Rapid Active Sampling Surveys as a Tool to Evaluate Factors Associated with Acute Gastroenteritis and Norovirus Infection among Children in Rural Guatemala.Recent advances in understanding norovirus pathogenesis.Norovirus Infections in Long-Term Care Facilities.

P2860

Q26749653-A16EC33B-FAF4-43A6-BE93-131145A825AD Q26783083-D2FA28BC-10E7-44C9-8205-18026AE16916 Q26799737-88668C29-C264-4C91-9AF4-3C86ABF087CE Q26864280-DA6AB059-44A5-4117-9E3E-2770D3DF2229 Q28083087-B47BE15F-86F2-47C7-B934-CD0693518719 Q30381028-13476FA3-2850-4AFD-84F8-78B9B790F0CE Q33455756-2B3390F4-3C28-4FE9-8489-52F6BB1BA294 Q33654573-870A2C5D-D495-4A0B-BADC-55D265521685 Q33703664-95F9CFB0-0ADA-40D4-B2B0-A1F3CFB97626 Q34452871-5CFE8182-C50C-4F71-810A-F8A6C24D4AD6 Q35212408-0948E1BC-6CA2-4A9F-8807-ED319C44BA71 Q35638367-1D68ACC7-BB2A-4D2F-935B-5E704B795ABC Q35744232-09368E1F-5DC0-401F-AE55-A3E8AE2E462A Q35749942-95F385B9-8C42-4411-9CB0-3BE785396AED Q35901978-3B86D88D-F401-4C7A-97D8-306322271BD0 Q35944776-3CA09FAE-D97F-4022-BCF1-38BC17767ED6 Q35999366-610DD9AA-DD80-4BB1-97C6-95ECB6E7C77C Q35999619-3012BB42-8F35-404B-B6DD-36A2A87C3F86 Q36048013-9B60BAB0-7D06-4D89-9EE1-E47A879EDBD3 Q36082874-A7E1C5D5-1477-47A8-83A2-34D7BD9BB16D Q36254157-CF88099D-0512-4C0C-97A0-699059F10EAA Q36275589-3AF6BE1D-51C0-4A0B-942E-B83F4E47B25B Q36344240-F0374049-946D-4431-876D-1101F1907E46 Q36373327-24370B07-3E2B-44EC-BD8F-01BFA3634B7D Q36642590-8919DC24-28BF-421F-9FD2-492C274059EC Q36728581-AE2C89F3-8457-474F-9A2B-22D070935B2A Q36907013-510FAF90-3B4D-4D1B-99CB-FAC9BC295DD4 Q37062340-310852F4-F1CC-45CF-A3BF-37183E4F12CB Q37135255-C7F982EB-1E8A-415A-B56D-EA5547F0D99F Q37135476-C05A653A-96EE-423F-9B10-C93890349828 Q37296094-E02ACDAF-9118-4EB2-A509-1D813694BF15 Q37375402-15E31415-7B69-498E-BAE7-FEE3C2356E32 Q37590280-A403C333-9D32-43C7-8C39-642B1442605A Q38280209-AC2CB035-A31C-4189-A3A8-8C05FF5956FD Q38374766-C7F63F63-C2E6-4444-A7F5-366BC1301956 Q38557262-8623C730-5C3C-48B8-85B8-946CEDB21A35 Q38645513-2AE61D97-33E0-4EC8-BFAD-AC9C278C7422 Q38672461-CC387576-311A-4A4F-BFBA-6F66A98731B9 Q38816488-1EA3C116-E5E8-4004-9753-B2DA90E7BFD4 Q38844351-F9F9EECA-FDE9-4B24-98EB-F569BCD245E4

P2860

Norovirus vaccine against experimental human GII.4 virus illness: a challenge study in healthy adults.

http://www.wikidata.org/entity/Q41743964

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Norovirus vaccine against expe ...... lenge study in healthy adults.

@en

type

label

Norovirus vaccine against expe ...... lenge study in healthy adults.

@en

prefLabel

Norovirus vaccine against expe ...... lenge study in healthy adults.

@en

P1433

Q41743964-4DC80C10-9854-47F4-BF2D-AB7DF046393F

P1476

Q41743964-A8FCB11A-59E3-4807-88E6-D859E63974BE

P2093

Q41743964-072AE4DB-CF70-4B18-B130-1D4835126203

Q41743964-0B67D097-E36B-4715-ACB6-BACD81FF3FCD

Q41743964-59008E12-125E-4A45-9166-D6E43F0A7741

Q41743964-605D8B55-D7CA-4A16-851E-14A256CE4F49

Q41743964-758CCC28-96DB-4099-A514-39700B8C1011

Q41743964-77EFFBEB-4180-4949-AA61-0114669EB93A

Q41743964-8546E63E-021D-42A2-A984-2DCE6FEFB5C1

Q41743964-8F479B11-86E4-4D47-81B7-EF6D42BB5A8C

Q41743964-9A483472-1DCD-417F-8C4D-63FA16769606

Q41743964-BD18EA70-BB74-47B8-862E-A8020EE71865

P2860

Q41743964-29E09868-EAEE-411C-B5C6-6FE88AE19021

Q41743964-38DD2EE1-5E29-4D9C-ABA3-925EDB7D9CF9

Q41743964-440B2340-4553-4EA5-B734-44DC8118B1B5

Q41743964-49AD306B-8B9D-4617-8796-140FD294744B

Q41743964-4FB1BAB1-1519-4B29-8171-E9DC3A69F42F

Q41743964-525D3C24-F806-479F-9FE8-19CB882C6EBC

Q41743964-53967F4D-54D2-425E-A63E-C4CA0CDA59D9

Q41743964-5AF51F45-165B-4208-8587-0350DD3723A1

Q41743964-743EA40A-8A93-401C-8699-F272DBC6209C

Q41743964-79A0A596-AFF0-41A7-AF86-8716B9A6DF8B

P304

Q41743964-B05D1697-EAA0-48A6-A54D-DE5750CF2979

P31

Q41743964-81190E9D-DAAE-4FB0-AB92-BC76FB992317

P356

Q41743964-FDA86C13-06C3-4ACA-B178-493897381E47

P407

Q41743964-5522EC0D-51BB-4F2A-8944-EB3CE6816394

P433

Q41743964-A0A9594E-DB9A-4F07-B8B2-59B1FB93E1AB

P478

Q41743964-6C5986D8-199F-4E3D-A195-364897327917

P50

Q41743964-006A23FC-8E15-40C8-9AE0-8C1B7D5422CD

Q41743964-169952AE-821A-4573-A3FE-83D738EB8CF5

Q41743964-1B1E4C43-37A9-4FD4-BEDB-F16FE8CE938F

Q41743964-3ECEBF99-F6CF-4C92-8EED-B899076829C7

Q41743964-5BED5F6D-734E-4641-B913-1EAC592A2044

P577

Q41743964-D380EB6F-9069-46FC-A713-CEF9843445CC

P5875

Q41743964-0396602C-7AA6-499D-A7C2-78996A03248F

P698

Q41743964-5E3A1233-7349-47EA-BEFA-3871322826AB

P921

Q41743964-F17CF1A8-773A-4EDE-94CE-7BA4A4C81ABF

P932

Q41743964-119BDBF7-A2EF-4F9E-8FB3-735CC13957B9

P356

P1433

The Journal of Infectious Diseases

P1476

Norovirus vaccine against expe ...... lenge study in healthy adults.

@en

P2093

Astrid Borkowski

http://www.w3.org/2001/XMLSchema#string

Christine L Moe

http://www.w3.org/2001/XMLSchema#string

David I Bernstein

http://www.w3.org/2001/XMLSchema#string

G Marshall Lyon

http://www.w3.org/2001/XMLSchema#string

Jennifer Ferreira

http://www.w3.org/2001/XMLSchema#string

Jill Barrett

http://www.w3.org/2001/XMLSchema#string

John J Treanor

http://www.w3.org/2001/XMLSchema#string

Mohamed S Al-Ibrahim

http://www.w3.org/2001/XMLSchema#string

Paul M Mendelman

http://www.w3.org/2001/XMLSchema#string

Ralf Clemens

http://www.w3.org/2001/XMLSchema#string

P2860

Foodborne illness acquired in the United States--major pathogens

Immunogenetic mechanisms driving norovirus GII.4 antigenic variation

Heterotypic humoral and cellular immune responses following Norwalk virus infection.

Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008.

Clinical and epidemiologic characteristics of norovirus GII.4 Sydney during winter 2012-13 in Beijing, China following its global emergence.

Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations.

Norovirus and medically attended gastroenteritis in U.S. children

Severe outcomes are associated with genogroup 2 genotype 4 norovirus outbreaks: a systematic literature review

Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues

Duration of immunity to norovirus gastroenteritis.

P304

870-878

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIU497

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

211

http://www.w3.org/2001/XMLSchema#string

P50

Nicole Gregoricus

David Y. Graham

P577

2014-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265558952

http://www.w3.org/2001/XMLSchema#string

P698

25210140

http://www.w3.org/2001/XMLSchema#string

P921

P932

5914500

http://www.w3.org/2001/XMLSchema#string